ORTHOVISC®

The Science of Ultra-High Molecular Weight HA — How ORTHOVISC® Restores Joint Function

In a healthy knee joint, hyaluronic acid gives synovial fluid its viscoelastic character — enabling it to act simultaneously as a lubricant during slow movement and a shock absorber under impact. In osteoarthritis, the molecular weight and concentration of naturally occurring HA in synovial fluid may decline, reducing these protective properties and contributing to friction, stiffness, and progressive joint pain. ORTHOVISC® is designed to address this by supplementing the joint with high-concentration, ultra-high-molecular-weight hyaluronic acid, injected directly into the knee. [1]

What sets ORTHOVISC® apart from standard viscosupplements is its molecular weight profile. Ultra-high MW HA provides stronger viscoelastic properties than lower-MW formulations — a distinction that matters clinically when selecting a viscosupplement intended to restore joint lubrication and mechanical cushioning rather than simply adding volume to synovial fluid. This positions ORTHOVISC® as a product worth evaluating on molecular characteristics, not just injection schedule. [1]

ORTHOVISC® contains hyaluronan in physiological saline and is supplied in a sterile single-use syringe. It is not a corticosteroid, stem cell therapy, or cell therapy product. Practitioners who encounter patients asking whether ORTHOVISC® is a steroid should clarify that it is a hyaluronic acid medical device that works through viscosupplementation, not through anti-inflammatory mechanisms. The HA is derived through bacterial fermentation — a non-avian source — which is clinically relevant for patient allergy screening and for product selection in patients who cannot receive avian-derived viscosupplements. [3][5]

It is also worth noting that high-MW viscosupplementation HA and aesthetic HA are not interchangeable product categories: practitioners looking for soft-tissue correction or facial volumization will find the right tools in dedicated aesthetic ranges — those who buy hyaluronic acid dermal fillers or buy dermal fillers are selecting for entirely different indications, administration depths, and regulatory classifications.

ORTHOVISC® Product Range and Spotlight

The ORTHOVISC® brand is centered on a multi-injection viscosupplementation format for knee osteoarthritis. Its standard treatment cycle consists of 3–4 weekly intra-articular injections, depending on the clinical protocol, payer requirements, and patient response. This staged approach allows practitioners to deliver HA support over multiple visits while monitoring the response throughout the treatment cycle. [4][5]

ORTHOVISC® 30 mg/2 mL intra-articular syringe is a single-use syringe that contains 30 mg of ultra-high-molecular-weight hyaluronan in physiological saline for intra-articular administration to the knee joint. One syringe is used per treated knee per weekly injection; if both knees require treatment, a separate syringe is needed for each. The 3–4 injection schedule gives practitioners clinical flexibility to adapt the course length to individual patient response and payer requirements while delivering high-MW HA support across the full cycle. [4][5]

ORTHOVISC® is the multi-injection product in Anika Therapeutics’ viscosupplementation portfolio. Its single-injection sibling, MONOVISC®, uses a related HA platform but is designed for a one-visit treatment cycle. Together, the two products offer practitioners format options — staged weekly dosing or single-visit convenience — from a single manufacturer, simplifying supplier management for clinics stocking both.

Practices expanding their knee OA offerings can explore orthopedic injections in the Doctor Medica catalog to evaluate how ORTHOVISC® fits alongside other viscosupplements before committing to a sourcing plan. Practitioners planning to buy ORTHOVISC® online should verify product presentation, LOT number, expiry, storage conditions, and documentation before clinical use.

Treatment Areas — Which Patients Benefit from ORTHOVISC® Injections?

ORTHOVISC® is indicated for pain associated with osteoarthritis of the knee in patients who have not responded adequately to conservative non-pharmacologic therapy and simple analgesics. The target patient is one who continues to experience knee pain, stiffness, and reduced mobility despite physical therapy, exercise, weight management, or over-the-counter analgesics, and who is seeking non-surgical pain management before considering more invasive intervention. Randomized controlled trial data support ORTHOVISC®’s efficacy across a range of knee OA severities, with clinically meaningful improvements in pain and function documented in treated patients. [1]

The approved US labeling covers only the knee joint. Clinical literature and some international materials reference viscosupplementation in other joints — hip, shoulder, ankle — but these represent uses outside ORTHOVISC®’s approved indication and should be evaluated against local regulations, available clinical evidence, and individual patient circumstances. References to shots for back or neck are not part of ORTHOVISC®’s labeled use and should be distinguished from approved knee-specific treatment. [5]

How ORTHOVISC® Is Administered — Injection Protocol and Clinical Considerations

ORTHOVISC® is administered by a qualified health care professional as an intra-articular injection into the knee joint. A standard ORTHOVISC® treatment cycle consists of one injection per week for 3 or 4 consecutive weeks. Each syringe treats one knee; if both knees require treatment, use a separate syringe for each. Product handling and injection technique should follow the current IFU, aseptic standards, and the practitioner’s facility protocol. [5]

Before each injection, the knee should be assessed for swelling, tenderness, active inflammation, or joint effusion. If excess fluid is present, aspiration may be performed at the practitioner’s discretion before injecting to support accurate product placement and patient comfort. ORTHOVISC® should not be injected into an infected joint or through skin affected by active infection or disease. [5]

Duration For ORTHOVISC® to Work

Response varies by patient. Some may notice relief after the first injection, while others experience gradual improvement as the treatment cycle progresses. Comparative clinical data suggest that while corticosteroid injections may produce faster initial relief, hyaluronic acid viscosupplementation — including ORTHOVISC® — may provide superior and more sustained pain relief at longer follow-up timepoints such as 15 weeks. [1][2] Because ORTHOVISC® is designed as a multi-injection regimen, clinical response is best assessed over the completed 3–4-week course rather than after a single session.

Why Orthopedic Practitioners Choose ORTHOVISC®

Practitioners choose ORTHOVISC® for two clinically grounded reasons.

1. Molecular Weight: ORTHOVISC®’s ultra-high MW HA formulation provides stronger viscoelastic properties than lower-MW HA products, giving it a differentiated profile as a lubricant and shock absorber in the osteoarthritic knee joint. Randomized controlled trial evidence supports meaningful pain relief and functional improvement with ORTHOVISC®, making the MW advantage a clinically documented rather than purely theoretical differentiator. [1]
2. Hyaluronic Acid (HA) Source: ORTHOVISC® is produced through bacterial fermentation — a non-avian manufacturing process — making it a suitable option for patients with allergies to avian proteins, feathers, eggs, or poultry who cannot safely receive avian-derived viscosupplements. For practices managing a heterogeneous patient population, having a non-avian high-MW option on hand expands the eligible patient pool without requiring a change of manufacturer or HA technology platform. [3]

Regulatory Status, Coverage, and Market Availability

ORTHOVISC® is an FDA-cleared hyaluronic acid medical device for the treatment of pain in osteoarthritis of the knee in patients who have not responded adequately to conservative non-pharmacologic therapy and simple analgesics. It is restricted to sale by, or on the order of, a physician or properly licensed practitioner. [4][5]

For billing, ORTHOVISC® is listed by CMS under HCPCS code J7324 per dose, with a 3–4 weekly injection schedule and 30 mg once-weekly dosing. CPT codes 20610 or 20611 may apply for intra-articular injection administration depending on payer requirements and ultrasound guidance. Does Medicare cover ORTHOVISC® injections? Coverage may apply under applicable CMS viscosupplementation criteria when medical necessity, diagnosis documentation, and prior therapy requirements are met. Practitioners should verify per-patient coverage and current local coverage determination policies before administering. [4]

ORTHOVISC® is available in the United States and other international markets where cleared or authorized. US labeling focuses on knee osteoarthritis; some international materials describe broader applications. Clinics sourcing ORTHOVISC® should verify the approved indication, distribution requirements, and local regulatory rules for their practice location. Because ORTHOVISC® is an orthopedic injectable rather than an aesthetic HA product, practitioners seeking soft-tissue correction or facial volumization will find those products in separate categories — those who buy hyaluronic acid dermal fillers or buy dermal fillers are working with a clinically and regulatorily distinct product class. [5]

About the Manufacturer — Anika Therapeutics

Anika Therapeutics is a US-based global medical technology company headquartered in Bedford, Massachusetts, focused on joint preservation, regenerative medicine, and hyaluronic acid-based orthopedic products. Its viscosupplementation portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL® — a range that reflects the company’s sustained investment in HA-based knee OA treatment across different product formats and patient needs. [5]

ORTHOVISC® and MONOVISC® together illustrate Anika’s portfolio strategy: both are built on the company’s HA platform and share a bacterial fermentation-derived non-avian source, but ORTHOVISC® serves the multi-injection segment while MONOVISC® addresses single-visit convenience. For clinics that order ORTHOVISC® and stock both products, this shared non-avian source simplifies patient screening while giving practitioners genuine format flexibility across treatment cycle preferences. Clinics preparing to purchase ORTHOVISC® should review the manufacturer’s IFU, current FDA documentation, storage requirements, and local market requirements before clinical use. [3][5]

ORTHOVISC® Safety Profile — Adverse Events and Contraindications

The safety profile of ORTHOVISC® is highly consistent with standard intra-articular hyaluronic acid viscosupplements. Most reported side effects are localized to the injection site or the treated joint, rather than systemic, and they typically resolve within a few days. [3][5]

Common Local Side Effects

Practitioners should advise patients that mild, transient reactions are common post-administration and include:

• Injection-site pain or localized tenderness
• Swelling and fluid accumulation around the joint
• Warmth or mild redness at the injection site
• Temporary joint stiffness

Post-Injection Protocol

Patients should be advised to avoid strenuous or prolonged weight-bearing activities (such as running, tennis, or heavy lifting) for approximately 48 hours after the injection. Instruct patients to report persistent pain, severe swelling, fever, or any signs of infection for immediate clinical evaluation. [5]

Absolute Contraindications

ORTHOVISC® must not be administered to patients presenting with:

• Known hypersensitivity to hyaluronate preparations.
• Active joint infections in the target knee.
• Skin diseases or active infections at or around the intended injection site. [5]

Clinical Screening & Allergy Considerations

Because ORTHOVISC® is derived via bacterial fermentation rather than avian sources, it does not carry the avian allergy contraindications (such as sensitivities to feathers, eggs, or poultry) common to rooster comb-derived products. [3]

However, robust patient screening remains vital before beginning each 3–4 week treatment cycle. A thorough pre-injection assessment should cover:

• Hypersensitivity or prior adverse reactions to hyaluronan itself.
• Current joint status and evaluation for any existing joint effusion.
• Active local or systemic infection risks.
• Concurrent use of anticoagulants or blood thinners.
• Prior clinical response to viscosupplementation therapies. [3][5]

How ORTHOVISC® Compares to Other Viscosupplements

ORTHOVISC® vs EUFLEXXA®

ORTHOVISC® and EUFLEXXA® are both non-avian hyaluronic acid viscosupplements. This shared characteristic distinguishes both from avian-derived competitors. Where they differ is in molecular weight profile and injection schedule: ORTHOVISC® is positioned as an ultra-high MW HA product administered over 3–4 weekly injections, while EUFLEXXA® is a non-cross-linked HA product typically administered over 3 injections. Practices building a non-avian HA offering that buy EUFLEXXA® alongside ORTHOVISC® can cover different molecular weight profiles and schedule preferences within a single non-avian product pairing. [3]

ORTHOVISC® vs MONOVISC®

ORTHOVISC® and MONOVISC® are both Anika Therapeutics products sharing a non-avian bacterial fermentation HA source, making this a comparison of format rather than technology or origin. The ORTHOVISC® treatment is spread across 3–4 weekly visits; MONOVISC® delivers it in one. For clinics where patient compliance with multi-visit protocols is reliable, ORTHOVISC® offers a staged approach; for patients where a single-visit option better fits their schedule or preference, practices that buy MONOVISC® alongside ORTHOVISC® can offer both without changing manufacturer or HA source. [3][5]

ORTHOVISC® vs SYNVISC®

ORTHOVISC® is an ultra-high MW, non-avian, bacterial fermentation-derived HA, while SYNVISC® uses cross-linked hylan G-F 20 and is avian-derived. The comparison involves HA source, cross-linking, molecular characteristics, and schedule — SYNVISC® is available in both multi-injection and single-injection formats, while ORTHOVISC® is a multi-injection product only. Clinics managing patients with avian protein sensitivities will find ORTHOVISC® the more appropriate choice; those stocking both can buy SYNVISC® to cover patients without such sensitivities. [3]

ORTHOVISC® vs HYALGAN®

ORTHOVISC® is an ultra-high MW non-avian HA product, while HYALGAN® is a lower-MW avian-derived sodium hyaluronate administered as a labeled five-injection weekly course. The comparison centers on molecular weight, HA source, treatment schedule, and avian allergy considerations: ORTHOVISC® is the appropriate choice for patients with avian protein sensitivities, while HYALGAN® remains a familiar option for payers and practices where that protocol is well established. Practices that buy HYALGAN® can position it alongside ORTHOVISC® to cover both avian and non-avian patient profiles within a single viscosupplementation offering. [3]

ORTHOVISC® vs SUPARTZ®

ORTHOVISC® and SUPARTZ® are both multi-injection viscosupplements for knee osteoarthritis, but they differ in their HA sources, molecular weights, and product positioning. While ORTHOVISC® is a non-avian ultra-high-MW HA product, SUPARTZ® is an avian-derived standard sodium hyaluronate administered as 3–5 weekly injections. For practices evaluating multi-injection options across different HA profiles and patient allergy profiles, those who buy SUPARTZ® can position it as an avian-source alternative to ORTHOVISC® within a broader viscosupplementation offering. [3]

Doctor Medica has supplied viscosupplementation and orthopedic injection products to licensed professionals since 2006, offering competitive wholesale prices, guaranteed authenticity, and verifiable LOT numbers. Licensed practitioners looking to buy ORTHOVISC® wholesale or when buying online can browse the Doctor Medica catalog or contact representatives for information on product availability, documentation, and clinical purchasing support.

FAQs

What is ORTHOVISC® used for?

ORTHOVISC® is used for pain associated with osteoarthritis of the knee in patients who have not responded adequately to conservative non-pharmacologic therapy and simple analgesics. It is a hyaluronic acid viscosupplement, not a steroid. [1][5]

What is ORTHOVISC® made of?

ORTHOVISC® contains ultra-high-molecular-weight hyaluronic acid in physiological saline, derived from bacterial fermentation. It is a non-avian HA product supplied in a sterile single-use syringe for intra-articular knee injection. [3][5]

How is ORTHOVISC® administered?

ORTHOVISC® is injected directly into the knee joint by a qualified health care professional. The standard treatment cycle consists of 3–4 consecutive weekly injections. If joint effusion is present, aspiration may be performed before injection. [4][5]

How long does it take for ORTHOVISC® to work?

Some patients may notice relief after the first injection; others experience gradual improvement across the full treatment cycle. Comparative data suggest HA viscosupplementation may provide superior sustained relief at longer follow-up compared with corticosteroid injections. [1][2]

How long do ORTHOVISC® side effects last?

Injection-site reactions such as pain, swelling, warmth, or stiffness are generally transient and typically resolve within a few days. Persistent pain, significant swelling, fever, or signs of infection should be evaluated promptly by a clinician. [3][5]

Is ORTHOVISC® a steroid?

No. ORTHOVISC® is not a corticosteroid. It is an ultra-high-molecular-weight hyaluronic acid medical device used for viscosupplementation in knee osteoarthritis. [1][5]

Is ORTHOVISC® a one-time injection?

No. The standard ORTHOVISC® treatment cycle consists of 3–4 weekly intra-articular injections, not a single treatment visit. [4][5]

Does Medicare cover ORTHOVISC® injections?

Coverage may apply under CMS viscosupplementation criteria when medical necessity, documentation of an OA diagnosis, and prior therapy requirements are met. Practitioners should verify per-patient coverage and current local coverage determination policies before administering. [4]

Where can medical professionals buy ORTHOVISC®?

Licensed practitioners can buy ORTHOVISC® through Doctor Medica, which supplies orthopedic injectables at wholesale prices with verifiable LOT numbers and documentation support. Contact representatives for product availability and professional purchasing assistance.

Citations

1. Neustadt D, Caldwell J, Bell M, Wade J, Gimbel J. Clinical effects of intraarticular injection of high molecular weight hyaluronan (Orthovisc) in osteoarthritis of the knee: a randomized, controlled, multicenter trial. Journal of Rheumatology. https://pubmed.ncbi.nlm.nih.gov/16206349/
2. Tekeoglu I, Adak B, Goksoy T, Tosun N. Comparative study: sodium hyaluronate (Orthovisc) vs betamethasone in knee osteoarthritis. Journal of Rheumatology and Medical Rehabilitation. 1998. https://hdl.handle.net/20.500.14720/17866
3. S. Department of Veterans Affairs. Intra-Articular Administration of Hyaluronic Acid or Hylan G-F 20. VA Formulary Advisor. 2020. https://www.va.gov/formularyadvisor/DOC_PDF/Hyaluronic_Acid_Hylan_G_F_20_Mar2020.pdf
4. Centers for Medicare & Medicaid Services. Billing and Coding: Intraarticular Knee Injections of Hyaluronan. Last Updated 06/18/2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56157&ver=15
5. Anika Therapeutics. Orthovisc for Knee OA Pain Relief. https://anika.com/products/oapm/orthovisc/

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.